Objective: To synthesize and characterize MCM-41-IL-4 and evaluates its immunomodulatory effect on Raw 264.7 cells. Methods: we synthesized and characterized MCM-41 type mesoporous silica nanoparticles (MSNs) and loaded it with interleukin 4 (IL-4); CCK-8 and live and dead staining were used to evaluate Raw 264.7 cell viability; Immunofluorescence was used to study morphology of Raw 264.7 cells; Quantitative real-time polymerase chain reaction (qRT-PCR)were used to study the gene expression of inflammatory factors of Raw 264.7 cells; After the stimulation of human umbilical vein endothelial cells (HUVECs) with MCM-41/RAW 264.7 and MCM-41-IL-4/ Raw 264.7 condition medium, the gene expression of angiogenic factor matrix metallopeptidase 9 (MMP9) and kinase insert domain protein receptor (VEGF) pathway-related factors from HUVECs was assessed by qRT-PCR. Results: MCM-41-IL-4 can stimulate the proliferation of RAW 264.7 cells; MCM-41-IL-4 can induce RAW 264.7 cells express more the F-actin; MCM-41-IL-4 can increase the expression of M2-related genes transforming growth factor, beta 1(Tgfb1), interleukin 1 receptor antagonist(IL-1ra)and arginase, liver (Arg-1) and decrease the expression of M1-related gene interleukin 6 (IL-6); Increased gene expression of MMP9 and platelet derived growth factor receptor alpha (PDGFRα) of HUVECs of MCM-41/Raw 264.7 condition medium was observed. Conclusion: MCM-41-IL-4 can stimulate the proliferation of RAW 264.7 cells, increase the expression of M2-related genes, decrease the expression of M1-related gene and induce the transformation of M2 macrophage which may be used as an immunomodulatory agent for bone tissue engineering applications.